A century ago, the discovery of penicillin marked a true revolution in medicine, saving millions of lives. Yet the rapid spread of antimicrobial resistance means that many antibacterial drugs are now losing their effectiveness. Bacteria are evolving, while the development of new antibacterial drugs remains a lengthy and costly process. This challenge is particularly acute in the treatment of tuberculosis, where specific mutations in the pathogen can reduce its susceptibility to antibacterial drugs.
This is precisely the issue addressed by a project implemented by researchers at the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine. With grant funding from the National Research Foundation of Ukraine, they conducted a study entitled “Site-directed mutagenesis as a novel strategy to investigate and overcome Mycobacterium tuberculosis antibiotic resistance”.
We asked the project PI, Professor Sergiy Yarmoluk, Corresponding Member of the National Academy of Sciences of Ukraine, what prompted the team to focus on this particular research topic.
“Antibiotic resistance is now one of the greatest threats to humanity, and that is no exaggeration”, says the researcher. “If we lose effective antibiotics, we could return to an era when a routine case of pneumonia, a post-operative infection or even a minor wound could once again become life-threatening”. Modern medical technologies would also be at risk, including organ transplantation, cancer treatment and complex surgery, all of which depend on effective antibiotics.
Another major concern is infections caused by bacteria circulating in hospitals which may be resistant to several, and in some cases nearly all, available drugs. Over the past few decades, only a few truly novel classes of antibiotics have been developed worldwide.
“That is why our aim was not simply to identify promising new compounds against tuberculosis, but also to investigate how changes in target enzymes can reduce susceptibility to these compounds. It is important to take such risks into account at an early stage in the development of potential new antibacterial drugs”, explains the PI.
How Bacteria Evade Antibiotics
“Genetic changes are constantly arising within bacterial populations. Under drug pressure, variants capable of surviving due to mutations may gain an advantage”, the professor continues. “If a mutation alters the drug’s molecular target, its effectiveness decreases”. The team’s task was to identify ‘weak points’ in bacterial proteins where mutations could reduce the effectiveness of potential drugs.
The researchers looked for inhibitors – compounds that ‘switch off’ vital enzymes in the tuberculosis bacterium and could serve as the basis for new drugs. In addition, they modelled individual amino acid substitutions in these enzymes that make the compounds bind less effectively to them and experimentally tested the selected substitutions. “This is not about literally predicting which mutations will necessarily arise in bacteria in the future but about assessing possible molecular mechanisms of resistance during the optimisation of compounds”, the researcher emphasises.
The research team brought together computational modelling, medicinal chemistry, molecular biology and biochemistry. They first carried out virtual screening of a library containing around 150,000 organic compounds. Using molecular docking, artificial intelligence methods and molecular dynamics, they selected compounds capable of binding to the active sites of the target enzymes. The most promising compounds were synthesised or selected for experimental validation. The researchers also obtained recombinant Mycobacterium tuberculosis enzymes and investigated the ability of the compounds to inhibit their activity.
A separate stage of the study involved site-directed mutagenesis, that is, a targeted change in a gene. The researchers introduced specific changes into the enzymes and compared the effects of the inhibitors on wild-type enzymes and their mutant forms. As a result, the team identified new promising inhibitors of two important enzymes of Mycobacterium tuberculosis and proposed a strategy for assessing how individual mutations may affect susceptibility to these compounds. Some of the findings have already been published in international scientific journals and have provided a basis for further research.
Improving the Early Stages of Drug Development
The results obtained could serve as a starting point for the further development of new anti-tuberculosis drugs. However, the potential significance of the project is broader: the proposed methodological strategy could be adapted to study other bacterial molecular targets in which mutations may confer resistance to antibiotics. “Even before costly preclinical studies begin, this strategy makes it possible to assess which changes in a molecular target could weaken the activity of a compound”, explains Professor Sergiy Yarmoluk. “This helps us make more informed choices when selecting promising candidates and determine directions for their further optimisation”.
One of the greatest challenges encountered during the research was the full-scale war. Some members of staff had to be evacuated, there were difficulties in procuring reagents and equipment, prolonged power outages occurred, and some experiments had to be postponed or departmental work schedules completely reorganised. Despite these challenges, the team managed to complete the project’s main objectives.
“The project was implemented by an interdisciplinary research team bringing together specialists in computational modelling, medicinal chemistry, molecular biology, biochemistry and biotechnology”, explains the PI. “Each person was responsible for their own part of the work, but everyone was working towards a common goal. It was this collaboration that made it possible to implement a highly complex project that could not have been completed by a single researcher or even a single department”.
A Grant Proposal Is Not Written in a Week
For researchers planning to apply to NRFU Calls for proposals for the first time, Sergiy Yarmoluk recommends paying attention to several key points. First and foremost, it is important to clearly define the scientific novelty of the project and demonstrate the potential practical significance of its findings. Despite the undeniable significance of fundamental research, it is equally important to explain how the knowledge gained could be applied in the future.
A strong research team is also essential, as modern science has long ceased to be the work of a single person. This is particularly relevant for Ukraine, where war and years of underfunding have left research institutions facing a shortage of highly qualified specialists and modern equipment. It is therefore important to work together, involve researchers from other departments, academic institutes and universities, and build teams with complementary expertise. The involvement of early-career researchers strengthens such teams and helps ensure continuity in research.
Another important piece of advice is to assess your capabilities realistically. “An application should include only those tasks that the research team is genuinely capable of completing”, cautions Sergiy Yarmoluk. “The NRFU monitors project implementation quite closely, so it is essential to submit reports on time and ensure that they accurately reflect the actual research findings. If a substantial proportion of the findings set out in the application is not achieved, this may negatively affect the possibility of receiving grants in the future”. And, of course, an application should be prepared well in advance, because a good grant proposal is not written in a week, it is built on years of scientific experience, previous experimental research and publications.
Interviewed by Svitlana GALATA